This study observes the efficacy and side effects of CT-guided radioactive iodine-125 seed brachytherapy in inoperable early stage non-small cell lung cancer retrospectively, and analyzes the influence of clinical and dosimetric factors on the outcomes.
Radioactive Iodine-125 seed brachytherapy is a conventional treatment in Peking University Third Hospital. Radioactive Iodine-125 seed brachytherapy is the implantation of Iodine-125 seed into tumors.The radioactive Iodine-125 seed can release low dose of irradiation persistently which kills tumors cell and causes less damage to normal tissue at the same time. This study collects the data of patients with early stage (stage I-II, N0) non-small cell lung cancer who underwent CT-guided radioactive Iodine-125 seed implantation from 2010 to 2018. The investigators evaluate the dose that covers 90% target volume(D90) and other parameters after the implantation. The efficacy and adverse effects were observed. Local control(LC) time and overall survival(OS) time are evaluated.
Study Type
OBSERVATIONAL
Enrollment
39
The radioactive Iodine-125 seed can release low dose of irradiation persistently which kills tumors cell and causes less damage to normal tissue at the same time. The treatment was performed under CT monitoring.
Local control time
The time from the date of seeds implantation to the date of recurrence of the implanted tumor or the date of last observation.
Time frame: Outcomes were followed up every 3 months after enrollment. The last follow-up timepoint is February 2019.
Overall survival time
The time from the date of seeds implantation to the date of death from any cause or the date of last observation.
Time frame: Outcomes were followed up every 3 months after enrollment. The last follow-up timepoint is February 2019.
Incidence of adverse events
The adverse events were evaluated by the common terminology criteria for adverse events (CTCAE). The rate of each adverse event was measured.
Time frame: Outcomes were followed up every 3 months after seeds implantation. The last follow-up timepoint is February 2019.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.